Kendle International (NASDAQ: KNDL) provides
a range of clinical development services to the biopharmaceutical industry. Offerings include clinical trial management, clinical data management, statistical analysis, medical writing, regulatory consulting and publication services. The company has expertise in a range of therapeutic areas, including oncology, cardiovascular disease, inflammation and central nervous system disorders. Kendle's Early Stage segment focuses on Phase I operations. The Late Stage unit handles Phase II through IV clinical trials, regulatory affairs, and biometrics offerings. Covance (NYSE: CVD) and Parexel International (NASDAQ: PRXL) are major competitors.
The firm surprised the Street earlier in the month, when it reported Q2 EPS of 52 cents and revenues of $127 million. Analysts had been looking for 46 cents and $115.3 million. The EPS figure was a company record. Management also guided FY08 EPS to $2.00-$2.15 ($1.90 consensus) and FY08 revenues to $490-$500 million ($468.76M consensus). Ladenburg Thalmann subsequently reiterated its "buy" recommendation and boosted its price target to $51.
Will Rich Ross really have a positive impact on Disney's movie operations?
Consumers sick of recession, may spend extra on holidays
Corrections, seasonality and Santa Claus
